Drug Profile
VA 111913
Alternative Names: VA 111913 TS; VA 913; VA111913Latest Information Update: 25 Aug 2015
Price :
$50
*
At a glance
- Originator Vantia Therapeutics
- Class Small molecules
- Mechanism of Action Vasopressin 1a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dysmenorrhoea
Most Recent Events
- 25 Aug 2015 No recent reports on development identified - Phase-II for Dysmenorrhoea in USA and United Kingdom (PO)
- 15 Nov 2010 Vantia completes a phase II trial in dysmenorrhoea in USA and United Kingdom
- 07 Oct 2009 Phase-II clinical trials in Dysmenorrhoea in United Kingdom (unspecified route)